Science

HUFFINGTON POST by Dr. Simin Nikbin Meydan                                                               April 21, 2015
When the world was devastated by the deadly outbreak of Ebola in West Africa last year, we were given a warning call on many levels. While I was mulling over the whys and hows of the epidemic, my mind automatically went to the role that nutrition can play in helping to stem the spread, and mortality rates, of diseases and perhaps deter future outbreaks.

 The next step my mind took, (admittedly, I research nutrition, immunology and infection in older adults), was to the role nutrition plays in maintaining a robust immune response and fighting against infections particularly in older adults. Remember the SARS outbreak in 2003? SARS (Severe Acute Respiratory Syndrome) is a viral respiratory disease caused by the SARS coronavirus. The outbreak began in southern China and caused an eventual 8,096 cases with 774 deaths reported in multiple countries. The overall mortality rate in aged populations exceeded 50%. Age matters in fighting infections. As we age, our immune systems gray and we need to factor this into our response to outbreaks.

It is telling that infectious epidemics usually originate in areas of the world that suffer from poor nutrition.

REUTERS by Kate Kelland                     April 21, 2015

LONDON, April 21 - Genetic sequence data on two of the deadliest yet most poorly understood viruses are to be made available to researchers worldwide in real time as scientists seek to speed up understanding of Ebola and MERS infections.

The project, led by British scientists with West African and Saudi Arabian collaboration, hopes to encourage laboratories around the world to use the live data -- updated as new cases emerge -- to find new ways to diagnose and treat the killer diseases, and ideally, ultimately, prevent them.

"The collective expertise of the world's infectious disease experts is more powerful than any single lab, and the best way of tapping into this...is to make data freely available as soon as possible," said Jeremy Farrar, director of the Wellcome Trust global health charity which is funding the work.

The gene sequences, already available for MERS cases and soon to come in the case of Ebola, will be posted on the website virological.org for anyone to see, access and use.

Read complete story.

http://af.reuters.com/article/topNews/idAFKBN0NC19W20150421?sp=true

PLOS MEDICINE   by Ben Cooper and others                                                             April 14, 2015
Experimental treatments for Ebola virus disease might reduce EVD mortality. There is uncertainty about the ability of different clinical trial designs to identify effective treatments, and about the feasibility of implementing individually randomised controlled trials during an Ebola epidemic

A treatment evaluation programme for use in EVD was devised using a multi-stage approach (MSA) with two or three stages, including both non-randomised and randomised elements. The probabilities of rightly or wrongly recommending the experimental treatment, the required sample size, and the consequences for epidemic outcomes over 100 d under two epidemic scenarios were compared for the MSA, a sequential randomised controlled trial (SRCT) with up to 20 interim analyses, and, as a reference case, a conventional randomised controlled trial (RCT) without interim analyses.

Read complete study.

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001815

NEW YORK TIMES OP-ED  By BERNICE DAHN, VERA MUSSAH and CAMERON NUTT   April 7, 2015               
MONROVIA, Liberia — The conventional wisdom among public health authorities is that the Ebola virus, which killed at least 10,000 people in Liberia, Sierra Leone and Guinea, was a new phenomenon, not seen in West Africa before 2013. (The one exception was an anomalous case in Ivory Coast in 1994, when a Swiss primatologist was infected after performing an autopsy on a chimpanzee.)